Abbvie Inc.

Abbott Laboratories Corporation

Abbvie Deutschland Gmbh and Co Kg

Abbott Gmbh & Co Kg

Abb Vie Deutschland Gmbh & Co. Kg

Bds Pharma Gmbh

Abbvie Bahamas Limited

Bit Pharma Gmbh

Abbvie Ireland Unlimited Company

Bernd Liepold

Gunther Berndl

Joerg Breitenbach

Laman L Alani

Soumojeet Ghosh

Ulrich Reinhold

Jörg Breitenbach

Joerg Rosenberg

Yi Gao

Thomas Kessler

Nancy E Sever

Drazen Kostelac

Jonathan Miller

Eric Allen Schmitt

Jörg Rosenberg

Yi Shi

Carl M Knable

Ping Gao

Mark Costello

John B Morris

Rajeev Gokhale

Peter Hoelig

Ute Lander

Mirko Pauli

Karin Rosenblatt

Fatih Durak

Anna Moosmann

J&ouml;rg Breitenbach

Kennan C Marsh

Christoph Schmidt

Markus Mägerlein

Markus Maegerlein

Peter Hölig

Peter Holig

Tina Jung

Claudia Packhaeuser

Jorg Breitenbach

Dirk Simon

Robert Heger

J&ouml;rg Rosenberg

Ulrich Westedt

Jianwei Wu

Didier Lefebvre

Martin Knobloch

Norbert Steiger

Rudolf Schroeder

Justin S Lafountaine

Gerd Woehrle

Steffen Bossmann

Benedikt Steitz

Susan George

Jöerg Rosenberg

Juergen Weis

Dietrich Granzow

Brent D Sinclair

Jürgen Weis

Claudia Henzel

Simon Kullmann

Jeorg Rosenberg

Madlen Thiel

Renato Koenig

Bryan K Erickson

Joeerg Rosenberg

Tanja Heitermann

Kennan Marsh

Justin Lafountaine

Peter HÖLIG

Leena Prasad

Cheri E Klein

Gunther Derndl

Yan Cai

Wolfgang Roth

Katja Fastnacht

Jorg Rosenberg

Claudia Packhäuser

A method is described for the production of dosage forms, which comprise a solid dispersion of a microcrystalline active substance, in which a thermoplastic polymer with a glass transition temperature Tg of at least 40&#xb0; C. is melted and an active substance is dissolved homogeneously in the melt; crystallization of the active substance is initiated in the mass obtained; and the mass is cooled. Crystallization of the active substance can be initiated by adding a nonsolvent, seed crystals of the active substance or a derivatization reagent. In addition, crystallization can be initiated by holding the mass for a sufficient length of time at a temperature that is below the temperature at which the active substance is completely soluble in the mass.

Production of dosage forms comprising a solid dispersion of a microcrystalline agent

A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.

Solid retard formulations based on solid dispersions

The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

Solid antiviral dosage forms

The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders.

Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor

Pharmaceutically acceptable solubilizing compositions comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono-and diester are disclosed. The solubilizing compositions are useful in the manufacture of pharmaceutical dosage forms comprising a melt-processed mixture of at least one active ingredient and at least one pharmaceutically acceptable polymer. The solubilizing compositions enhance the bioavailability of the active ingredient following oral intake.

Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same

A liquid mixture, comprising a) at least one compound selected from polyols, polyol ethers wherein at least one hydroxyl group is unetherified, or polyalkylene ethers wherein at least one terminal hydroxyl group is unetherified, b) 1,3-bis(caprolactam-1-yl) butane, and c) diacetoxybutane mimics the solubility properties of a graft copolymer comprising a poly(alkylene glycol) backbone and a vinyl acetate/N-vinylcaprolactam copolymer grafted onto the backbone. In a method for evaluating the compatibility of a biologically active substance with the graft copolymer i) the biologically active sub-stance is brought into contact with the liquid mixture, and ii) the phase behavior of the test system and/or the solubility of the biologically active substance in the mixture is determined.

Test solvent for evaluating the compatibility of biologically active substances and graft copolymers

A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.

Pharmaceutical dosage form comprising polymeric carrier composition

A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake.

A delivery system for sustained release of a calcium-channel blocking agent is adapted for introduction in the cerebrospinal fluid of a subject. The delivery system comprises a solid dispersion product of a calcium-channel blocking agent in a mixture of a (i) first poly(lactide-co-glycolide) having a molecular weight distribution centered around a first number average molecular weight Mnand a (ii) second poly(lactide-co-glycolide) having a molecular weight distribution centered around a second number average molecular weight Mn, wherein Mnis in the range of from 2000 to 3000 g/mol and the ratio of Mn/Mnis from 1.8 to 3.5. The delivery system is deposited in the vicinity of or adjacent to a blood vessel showing vasospasm or suspected of developing vasospasm.

Delivery system for sustained release of a calcium-channel blocking agent

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50&#xb0; C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Solid pharmaceutical dosage form

The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

Solid compositions

The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.

Solid pharmaceutical dosage formulation

Growing community of inventors

Dossenheim, Germany

Bernd Liepold